Stephanie L. Graff, MD, FACP

Articles

Leveraging TAILORx Findings to Guide Testing and Treatment Decisions in Node-Negative Breast Cancer

May 15th 2025

Panelists discuss how the TAILORx trial data were transformative for estrogen receptor–positive breast cancer by establishing clearer thresholds for chemotherapy benefit, while raising important questions about whether younger patients with intermediate scores benefit from chemotherapy itself or from the ovarian suppression it causes.

Using RxPONDER Findings to Inform Testing and Treatment Approaches in Node-Positive Breast Cancer

May 15th 2025

Panelists discuss how the RxPONDER trial data transformed breast cancer treatment by demonstrating that postmenopausal women with 1 to 3 positive lymph nodes and low recurrence scores could safely avoid chemotherapy, while highlighting the controversy about chemotherapy benefit in premenopausal patients where clinical judgment and nuanced assessment of menopausal status remain crucial.

Utilizing the RSClin Tool to Inform Breast Cancer Treatment Decisions in the Practice Setting

May 8th 2025

Panelists discuss how the RSClin tool provides more personalized information by combining recurrence scores with clinicopathological data, offering patients specific predictions about their prognosis and potential chemotherapy benefit rather than general outcomes for patients with similar scores.

Expert Insights on Genomic Test Selection in Breast Cancer: Strategies for Node-Negative vs Node-Positive Disease

May 8th 2025

Panelists discuss how clinical factors such as nodal status influence genomic testing decisions, referencing the TAILORx and RxPONDER trials whose data demonstrated that chemotherapy benefit varies based on recurrence score and menopausal status, highlighting the need for nuanced shared decision-making rather than strict cutoffs.

Genomic Assays in Breast Cancer: Key Differences, Clinical Utility, and Test Selection

May 1st 2025

Panelists discuss how they primarily use the 21-gene assay (Oncotype DX) for estrogen receptor–positive (ER+), HER2-negative (HER2–) breast cancers with minimal nodal disease due to its robust data from multiple trials, whereas other assays such as the Breast Cancer Index (BCI) are better for evaluating extended endocrine therapy benefits.

Optimizing Genomic Testing in Breast Cancer: Strategies for Community Practitioners

May 1st 2025

Panelists discuss how community practitioners face challenges with genomic testing due to working across multiple hospitals with different medical oncology groups who may have varying preferences for assays, emphasizing the importance of communication, established algorithms, and leveraging partnerships with testing companies.

Genomic Testing in Early-Stage Breast Cancer: Institutional and Multidisciplinary Perspectives

April 24th 2025

Discover essential insights on breast cancer awareness, prevention, and treatment options to empower your health journey.

Genomic Testing in Breast Cancer: A Predictive and Prognostic Tool in an Evolving Landscape

April 24th 2025

Discover essential insights on breast cancer awareness, prevention, and treatment options to empower your health journey.

Dr Graff on Fertility Preservation Strategies in Breast Cancer

January 15th 2025

Stephanie L. Graff, MD, FACP, FASCO, discusses current strategies for fertility preservation in patients with breast cancer.

Dr Graff on the Efficacy and Safety of GnRH Agonists for Premenopausal Women With Breast Cancer

January 15th 2025

Stephanie L. Graff, MD, FACP, FASCO, discusses data supporting the use of GnRH agonists for premenopausal women with breast cancer undergoing chemotherapy.

Wrapping up the Pivotal Highlights From SABCS 2024 With Drs Bora Lim and Stephanie Graff

December 13th 2024

Bora Lim, MD, of The University of Texas MD Anderson Cancer, and Stephanie Graff, MD, of Brown University Health, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in breast cancer presented during the 2024 San Antonio Breast Cancer Symposium.

Park and Graff Explore the Evolving Role of CDK4/6 Inhibitors in Metastatic Breast Cancer

September 4th 2024

Drs Park and Graff discuss the evolution of treatment for patients with metastatic HR-positive breast cancer, including the role of CDK4/6 inhibitors.

Breast Cancer Experts Share Obstacles and Successes as Women in Oncology

April 11th 2024

Drs Graff, Mahtani, McCann, and Rugo share moments that sparked their interest in oncology and setbacks they overcame when building their careers.

Dr Graff on the Trajectory of Her Career in Breast Cancer

March 11th 2024

Stephanie L. Graff, MD, discusses the trajectory of her career growth in breast oncology and explains how different factors can play a role in an oncologist’s career path.

Dr Graff on the Relation Between ctDNA Positivity and Disease Recurrence in HR+/HER2– Breast Cancer

December 7th 2023

Stephanie L. Graff, MD, discusses findings from a pilot study exploring the association between disease recurrence and circulating tumor DNA positivity in patients with hormone receptor–positive, HER2-negative, node-positive, high-risk, early breast cancer who have received adjuvant treatment of abemaciclib and endocrine therapy.

Dr Graff on the Impact of Endocrine Therapy Interruption on Conception in Breast Cancer Survivors

September 19th 2023

Stephanie L. Graff, MD, discusses the advantages of interrupting endocrine therapy in premenopausal patients with endocrine-responsive breast cancer who are seeking to conceive, based on findings from the phase 3 POSITIVE trial.

What is on the Horizon for Adjuvant Therapy in Early-Stage Breast Cancer?

August 17th 2023

Expert medical oncologists take a step into the future and discuss developments within the adjuvant setting of early-stage breast cancer they are most excited about.

Managing Toxicities and Adverse Events of CDK 4/6 Inhibitors

August 10th 2023

Stephanie Graff, MD, and Rachel Layman, MD, review common toxicities and adverse effects to watch out for with endocrine therapy and CDK4/6 inhibitors, and how to manage these.

Impact of Trial Data on Clinical Practice

August 10th 2023

Expert medical oncologists talk about the impact of NATALEE trial data on their medical practice.

Key Findings from the NATALEE Trial

August 3rd 2023

Stephanie Graff, MD, and Rachel Layman, MD, discuss the design and results of the NATALEE trial, which evaluated adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer.